Industry Watch [to 10 October 2015]

.
:: Johnson & Johnson Announces Start of Clinical Trial of Ebola Vaccine Regimen in Sierra Leone
Oct 09, 2015 [see Ebola coverage above]

:: Pfizer’s Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA® When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adolescents
October 09, 2015
Pfizer Inc. (NYSE:PFE) announced today that researchers presented for the first time data from a randomized, controlled Phase 2 study…

:: Focus on International Cooperation for Global Access to Vaccines at the DCVMN 16th Annual AGM
October 06, 2015
Under the auspices of the Queen Saovabha Memorial Institute (QSMI) of the Thai Red Cross Society and BioNet-Asia, the 16th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network…

:: Global Pharmaceutical Associations Welcome MEDICRIME Convention, Landmark Tool to Curb Global Medicines Counterfeiting IFPMA –
01 October 2015

:: PhRMA Statement On the TransPacific Partnership Negotiations
Washington, D.C. (October 5, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO, John Castellani, issued the following statement:
“PhRMA believes that strong intellectual property protection is necessary for the discovery and development of new treatments and therapies for the world’s patients.
“We are disappointed that the Ministers failed to secure 12 years of data protection for biologic medicines, which represent the next wave of innovation in our industry. This term was not a random number, but the result of a long debate in Congress, which determined that this period of time captured the appropriate balance that stimulated research but gave access to biosimilars in a timely manner.